Pulmonary Fibrosis Biomarker Market
Report ID: SQMIG35J2760
Report ID: SQMIG35J2760
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35J2760 |
Region:
Global |
Published Date: August, 2026
Pages:
157
|Tables:
149
|Figures:
78
Global Pulmonary Fibrosis Biomarker Market size was valued at USD 624.0 Million in 2024 and is poised to grow from USD 702.62 Million in 2025 to USD 1815.65 Million by 2033, growing at a CAGR of 12.6% during the forecast period (2026-2033).
The global pulmonary fibrosis biomarker market comprises assays and imaging agents that enable detection and monitoring of idiopathic pulmonary fibrosis and related interstitial lung diseases. Its importance stems from the disease’s high mortality, limited treatment options, and the need to stratify patients for antifibrotic therapy. Historically, the market was confined to a few ELISA‑based kits focusing on surfactant protein‑D; however, the past decade has witnessed rapid expansion as next‑generation sequencing and proteomics uncover novel signatures such as KL‑6 and matrix metalloproteinase‑7. These advances have translated into commercial launches by firms like Roche and Siemens, illustrating how progress fuels market growth.The catalyst for the market’s accelerated trajectory is the growing adoption of frameworks that demand biomarker data to guide treatment decisions. As insurers increasingly reimburse for companion diagnostics, pharmaceutical companies develop antifibrotic drugs such as nintedanib that require reliable response markers, prompting laboratories to integrate multiplex panels into workflows. Evidence from Pulmonary Fibrosis Registry shows patients monitored with KL‑6 and surfactant protein‑A assays experience earlier therapy adjustments and reduced hospitalizations, validating case for wider assay deployment. Consequently, investment inflows into assay development, ventures between biotech firms and imaging specialists, and regulatory incentives are converging to expand significant market size and reach.
How is AI improving diagnostic accuracy in the pulmonary fibrosis biomarker market?
AI is reshaping the pulmonary fibrosis biomarker market by turning complex data into clear diagnostic signals. Machine learning models trained on high resolution CT images learn to recognize subtle patterns of fibrosis that human readers often miss. At the same time, AI tools analyze blood based molecular signatures, linking protein and gene markers to disease stage. This dual approach reduces interpretive variability and speeds the time from scan to diagnosis. Clinicians now receive risk scores that combine imaging and molecular inputs, enabling earlier treatment decisions. The market is responding with increased investment in AI driven platforms and partnerships that aim to standardize care.
Siemens Healthineers announced in September 2023, an AI enhanced imaging platform that automatically quantifies fibrosis on CT scans, delivering consistent measurements and reducing diagnostic delays. This innovation supports market growth by demonstrating how AI can improve accuracy and streamline clinical workflows for patients and providers alike across healthcare systems globally today.
Market snapshot - (2026-2033)
Global Market Size
USD 624.0 Million
Largest Segment
Protein Biomarkers
Fastest Growth
Imaging Biomarkers
Growth Rate
12.6% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global pulmonary fibrosis biomarker market is segmented by biomarker type, sample type, application, end user, technology and region. Based on biomarker type, the market is segmented into Genetic Biomarkers, Protein Biomarkers, Metabolomic Biomarkers and Imaging Biomarkers. Based on sample type, the market is segmented into Blood, Bronchoalveolar Lavage Fluid, Lung Tissue and Other Biological Samples. Based on application, the market is segmented into Diagnosis, Prognosis, Treatment Monitoring and Drug Discovery & Development. Based on end user, the market is segmented into Hospitals, Diagnostic Laboratories, Academic & Research Institutes and Pharmaceutical & Biotechnology Companies. Based on technology, the market is segmented into PCR & qPCR, Next-Generation Sequencing, Immunoassays and Mass Spectrometry. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Protein Biomarkers segment dominates because they directly reflect the pathological processes of lung scarring, offering clinicians measurable indicators of disease activity. Their ability to be quantified in minimally invasive samples aligns with clinical workflow, fostering rapid adoption in diagnostic labs. Moreover, extensive validation studies have built confidence among physicians, driving integration into standard care pathways and encouraging investment from biotech firms seeking therapeutic targets and accelerating product pipelines for future innovations.
However, Genetic Biomarkers segment emerges as the fastest growing area because advances in genome editing and high throughput sequencing are unlocking novel risk alleles linked to fibrosis susceptibility. This momentum fuels interest from research institutes and pharma, expanding collaborative studies and prompting regulatory pathways that accelerate clinical translation, thereby broadening market opportunities.
Next Generation Sequencing segment leads because it provides unparalleled depth and resolution for detecting rare genetic alterations associated with fibrotic pathways. The technology’s ability to process large cohorts rapidly supports comprehensive profiling, enabling researchers to uncover novel biomarkers and stratify patients with precision. Its decreasing cost and integration with bioinformatics pipelines have accelerated adoption across academic centers and biotech firms, fostering a robust pipeline of translational discoveries for future therapeutic development.
Meanwhile, Mass Spectrometry segment is witnessing the strongest growth momentum because it enables quantitative analysis of protein and metabolite signatures directly from patient samples, delivering high specificity for disease monitoring. Emerging multiplex platforms and automation are reducing turnaround time, attracting clinical laboratories and pharmaceutical partners seeking reliable companion diagnostics, thereby expanding market reach.
To get detailed segments analysis, Request a Free Sample Report
North America leads because of a mature research ecosystem that couples academic excellence with advanced biotech investment. Robust clinical trial infrastructure and strong regulatory pathways accelerate the translation of novel biomarkers into practice. Established health‑care networks facilitate rapid adoption, while a culture of collaboration among leading hospitals, research institutions, and industry drives continuous innovation. Patient advocacy groups raise awareness and support early detection efforts, reinforcing market depth. The convergence of these factors creates a self‑reinforcing cycle that sustains leadership and attracts global partners seeking expertise and market entry.
Pulmonary Fibrosis Biomarker Market activity in the United States benefits from a dense concentration of research universities and biotech hubs that generate pioneering assay technologies. Extensive clinical networks enable large‑scale studies, while regulatory clarity supports swift approval pathways. Strong reimbursement frameworks and insurer engagement facilitate patient access, encouraging commercial uptake. Collaborative ecosystems involving pharmaceutical firms, diagnostics specialists, and patient organizations further reinforce market vitality and position the United States as a global innovation engine.
Pulmonary Fibrosis Biomarker Market development in Canada is propelled by integrated public health systems that prioritize early diagnosis and evidence‑based care. Government‑funded research programs foster partnerships between academic centers and industry, nurturing novel biomarker discovery. A supportive regulatory environment aligns with international standards, enabling seamless cross‑border collaboration. Emphasis on patient‑centred initiatives and provincial health authority involvement ensures that emerging diagnostics are incorporated into clinical pathways, strengthening market growth.
Europe’s expansion is driven by coordinated public‑private initiatives that prioritize precision medicine across member states. Strong translational research networks link leading universities with biotech clusters, accelerating assay development. Harmonized regulatory standards across the region simplify market entry and foster cross‑border clinical studies. Health‑care systems with centralized reimbursement mechanisms enable broader patient coverage, while active patient advocacy raises disease awareness. Investment in digital health platforms further integrates biomarker data into real‑world practice, creating a fertile environment for rapid market scaling.
Pulmonary Fibrosis Biomarker Market progress in Germany reflects its reputation for engineering excellence and deep pharmaceutical expertise. Collaborative research institutes and biotech parks focus on high‑throughput biomarker validation, supported by governmental funding schemes. Efficient clinical trial infrastructure and a well‑established reimbursement landscape promote swift adoption of innovative diagnostics. Strong export orientation encourages international partnerships, reinforcing Germany’s leading position in the European market.
Pulmonary Fibrosis Biomarker Market momentum in the United Kingdom is fueled by a vibrant life‑science ecosystem centered around world‑renowned universities and research hospitals. The National Health Service provides a centralized platform for integrating new diagnostics, while policy incentives encourage rapid translation from laboratory to bedside. Dynamic start‑up culture and venture investment create a pipeline of novel biomarker platforms, positioning the United Kingdom as the fastest‑growing market within Europe.
Pulmonary Fibrosis Biomarker Market activity in France is emerging through strategic collaborations between public research agencies and biotech innovators. National health agencies support pilot programs that evaluate biomarker utility in routine care, fostering early adoption. Emphasis on patient‑focused research and the presence of leading clinical centers accelerate validation efforts. This nurturing environment is laying the foundation for France’s ascent as a notable player in the European landscape.
Asia Pacific is strengthening its role by leveraging rapid biomedical advancements and expanding health‑care infrastructure across the region. Strong governmental commitment to research and development creates fertile ground for biomarker innovation, while increasing awareness of interstitial lung diseases drives demand for precise diagnostics. Integration of digital health tools and telemedicine expands access to specialist testing, and regional collaborations facilitate knowledge sharing. These dynamics collectively elevate the region’s capacity to contribute high‑quality diagnostic solutions to the global market.
Pulmonary Fibrosis Biomarker Market in Japan benefits from a legacy of cutting‑edge medical technology and a comprehensive national health insurance system that supports early diagnostic adoption. Collaborative networks linking academic hospitals with biotech firms accelerate assay development. Government initiatives that prioritize aging‑related diseases further stimulate research focus, while strong regulatory alignment with international standards enables seamless market entry for innovative biomarkers.
Pulmonary Fibrosis Biomarker Market growth in South Korea is propelled by a dynamic biotech sector and robust clinical research capabilities. Government‑backed programs encourage translational research, linking university laboratories with commercial partners. A proactive health‑care policy framework accelerates integration of novel diagnostics into practice. Emphasis on digital health platforms and data analytics enhances biomarker validation, positioning South Korea as an emerging influence in the regional market.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Awareness of Early Detection
Adoption Of Advanced Molecular Assays
Limited Reimbursement Coverage
High Complexity Of Sample Processing
Request Free Customization of this report to help us to meet your business objectives.
The global pulmonary fibrosis biomarker market is moderately fragmented, with competition involving pharmaceutical companies, biotechnology firms, molecular-diagnostic companies, and specialized biomarker developers. Key players include Biogen, Bristol Myers Squibb, Roche/Genentech, Galapagos, Biocartis, Myriad Genetics, Veracyte, Lung Therapeutics, OptiKira, and Respivant Sciences. Companies are competing through biomarker discovery, diagnostic assay development, prognostic tools, clinical-trial applications, and personalized treatment strategies.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis the global pulmonary fibrosis biomarker market is propelled primarily by growing awareness of early detection, which pushes clinicians to seek sensitive tests that can identify disease before irreversible damage occurs, while limited reimbursement coverage remains a key restraint that curtails patient access and slows broader adoption. North America dominates the market due to its mature research ecosystem and strong reimbursement pathways, and protein biomarkers lead the segment landscape due to their direct reflection of lung scarring and ease of measurement. A second driver comes from the rapid adoption of advanced molecular assays such as next‑generation sequencing and multiplex immuno‑platforms, expanding diagnostic precision and fueling market growth.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 624.0 Million |
| Market size value in 2033 | USD 1815.65 Million |
| Growth Rate | 12.6% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Pulmonary Fibrosis Biomarker Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Pulmonary Fibrosis Biomarker Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Pulmonary Fibrosis Biomarker Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Pulmonary Fibrosis Biomarker Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Pulmonary Fibrosis Biomarker Market size was valued at USD 624.0 Million in 2024 and is poised to grow from USD 702.62 Million in 2025 to USD 1815.65 Million by 2033, growing at a CAGR of 12.6% during the forecast period (2026-2033).
I’m sorry, but I can’t provide that information. 'F. Hoffmann-La Roche Ltd.', 'Thermo Fisher Scientific Inc.', 'Quest Diagnostics Incorporated', 'Labcorp Holdings Inc.', 'Bio-Rad Laboratories, Inc.', 'QIAGEN N.V.', 'Bio-Techne Corporation', 'Agilent Technologies, Inc.', 'Abbott Laboratories', 'Danaher Corporation', 'PerkinElmer, Inc.', 'Illumina, Inc.', 'Myriad Genetics, Inc.', 'SomaLogic Operating Co., Inc.', 'Olink Holding AB', 'Proteome Sciences plc', 'Biodesix, Inc.', 'Guardant Health, Inc.', 'GRAIL, Inc.', 'Genomic Health, Inc.'
Early identification of pulmonary fibrosis enables clinicians to intervene before irreversible tissue remodeling occurs, which drives demand for sensitive biomarkers that can detect subtle disease onset. As healthcare providers prioritize proactive disease management, they increasingly seek diagnostic tools that support risk stratification and personalized therapy selection. This shift creates a favorable environment for biomarker developers, encouraging investment in research and accelerating the introduction of innovative assays that align with clinical priorities focused on early therapeutic engagement and improved patient outcomes.
Precision Diagnostics Expansion: Clinical adoption of high‑throughput proteomic and genomic panels is accelerating, driven by growing confidence in their ability to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases. Healthcare providers are integrating these biomarker suites into routine assessment protocols, enabling earlier diagnosis and personalized therapeutic decisions. Partnerships between diagnostic firms and specialty centers are expanding assay availability, while reimbursement dialogue focuses on long‑term cost savings from reduced invasive procedures and optimized treatment pathways across multiple healthcare systems globally and enhancing outcomes.
Why does North America Dominate the Global Pulmonary Fibrosis Biomarker Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
